Veracyte, Inc. (VCYT) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. At $48.54, A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Decipher Prostate and Afirma tests; Concentration risk — Supplier: sole suppliers for reagents, equipment, and materials.
Veracyte is a global diagnostics company offering molecular tests for cancer including Decipher Prostate, Afirma (thyroid), Prosigna (breast), and Decipher Bladder, performed in CLIA labs in California and Texas plus IVD distribution internationally. Revenue comes from testing... Read more
Sell if holding. At $48.54, A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Decipher Prostate and Afirma tests; Concentration risk — Supplier: sole suppliers for reagents, equipment, and materials. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.6/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 51d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-15Recent Developments — Veracyte, Inc.
Latest news
- NEWS Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance Singapore — Yahoo Finance Singapore positive
- NEWS Earnings Flash (VCYT) Veracyte, Inc. Posts Q1 Adjusted EPS $0.52 per Share - marketscreener.com — marketscreener.com positive
- NEWS Wall Street analysts think Veracyte (VCYT) could surge 39.16%: Read this before placing a bet - MSN — MSN positive
- NEWS Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet - Zacks Investment Researc — Zacks Investment Research positive
- NEWS A Look At Veracyte (VCYT) Valuation As New Decipher Bladder And Prostate Data Heads To AUA 2026 - Yahoo Finance — Yahoo Finance positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDecipher Prostate and Afirma tests10-K Item 1A: 'financial results currently depend mainly on sales of our Decipher Prostate and Afirma laboratory developed tests (LDTs)'
- MEDIUMCustomerMedicare Fee-For-Service34%10-K Item 1: 'Medicare Fee-For-Service accounted for 34%, 33% and 35% of our testing revenue'
- HIGHSuppliersole suppliers for reagents, equipment, and materials10-K Item 1A: 'We rely on sole suppliers for some of the reagents, equipment, and other materials used to perform or develop our tests, as well as certain sole source providers for kit components'
Material Events(8-K, last 90d)
- 2026-03-16Item 5.02LOWVeracyte appointed Dr. Kevin Haas (age 40), former CTO at Myriad Genetics, as Chief Development and Technology Officer effective March 24, 2026. New role; no departure cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $48.54, A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Decipher Prostate and Afirma tests; Concentration risk — Supplier: sole suppliers for reagents, equipment, and materials. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $45.16. Score 5.6/10, moderate confidence.
Take-profit target: $49.53 (+2.0% upside). Prior stop was $45.16. Stop-loss: $45.16.
Concentration risk — Product: Decipher Prostate and Afirma tests; Concentration risk — Supplier: sole suppliers for reagents, equipment, and materials; Analyst target reached - limited upside remaining.
Veracyte, Inc. trades at a P/E of 43.8 (forward 24.9). TrendMatrix value score: 4.7/10. Verdict: Sell.
18 analysts cover VCYT with a consensus score of 4.2/5. Average price target: $49.
What does Veracyte, Inc. do?Veracyte is a global diagnostics company offering molecular tests for cancer including Decipher Prostate, Afirma...
Veracyte is a global diagnostics company offering molecular tests for cancer including Decipher Prostate, Afirma (thyroid), Prosigna (breast), and Decipher Bladder, performed in CLIA labs in California and Texas plus IVD distribution internationally. Revenue comes from testing services billed to Medicare (34%), Medicare Advantage (18%), and commercial payers (47%).